Navigation Links
BioXpress Therapeutics SA to Partner the 2011 BIO International Convention
Date:6/15/2011

GENEVA, Switzerland, June 15, 2011 /PRNewswire/ -- BioXpress Therapeutics SA, a Swiss-based biotechnology company developing high-quality monoclonal antibody (MAb) biosimilars announced today representatives from the Company will be partnering at the 2011 BIO International Convention's One-on-One Partnering Meetings being held Jun 27-30 in Washington, D.C. at the Walter E. Washington Convention Center.  

BioXpress Therapeutics currently has 4 biosimilar monoclonal antibody drugs in development with an additional 14 in the pipeline.

Representatives available to discuss partnering opportunities include:  Dr. Cori Gorman and Dr. Curt Scribner.  Companies or individuals attending BIO 2011 can schedule meetings with BioXpress Therapeutics by visiting (registration required):  oneononepartnering.bio.org/BusinessForum2011/Login.aspx.  

BioXpress Therapeutics Partnering Schedule:
Monday, June 27 Business Forum  -  12:00 PM - 5:00 PM
Tuesday, June 28 Business Forum  -  7:00 AM – 6:00 PM
Wednesday, June 29 Business Forum  -  7:00 AM – 6:00 PM
Thursday, June 30 Business Forum  -  7:00 AM – 6:00 PM

Each BioXpress Therapeutics biosimilar MAb is developed under strict non-clinical and clinical guidelines as outlined in the European Medicines Agency's "Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies."   Furthermore, each BioXpress Therapeutics biosimilar goes through a complete analytical comparison to determine the product is similar to the innovator product.

Having the correct primary sequence is absolutely critical for a biosimilar to have similarity and comparability to the innovator drug. Typically, there are several sequences published for every marketed monoclonal antibody. To ensure BioXpress Therapeutics has identified the correct sequence, the Company has developed a proprietary database of protein sequences based on comprehensive analysis of literature and patent databases. All data entry and data analysis is done by the Company's team which consists of scientists who have been actively involved in making monoclonal antibody therapeutics since the early 1980s. As a result, the BioXpress scientific team is well-versed in the literature and groups who have developed many of the originator MAbs over the decades. Based on the data from the BioXpress database, the biosimilar protein is expressed and compared to the originator to ensure a valid sequence before moving the drug forward.

About BioXpress Therapeutics

BioXpress Therapeutics SA is a privately held biotechnology committed to developing and supplying the highest quality and cost-competitive biosimilar biologic API for unmet need indications such as cancer, inflammation and autoimmunity.  Headquartered in Geneva, Switzerland, BioXpress Therapeutics business is focused on developing unbranded monoclonal antibody (MAb and MAb-like) biosimilar drugs under strict European Medicines Agency (EMA) guidelines.

For more information visit www.bioxpress.com.

Media Contact

Robert Meister
602-953-1716
robert@meister.net


'/>"/>
SOURCE BioXpress Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Arcion Therapeutics to Present ARC-4558 Phase 2b Data for the Treatment of Pain Associated With Painful Diabetic Neuropathy at Upcoming Medical Meetings
2. Cell Therapeutics on Preliminary List of Additions to Russell 3000® Index and Russell Global Index
3. Northwest Biotherapeutics Announces Change and Expansion of Management Team
4. Northwest Biotherapeutics Announces Series of Financing Arrangements
5. Healthpoint Biotherapeutics Acquires Regranex® Gel
6. Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
7. Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017
8. Juventas Therapeutics Demonstrates JVS-100 Delivery to Patients with Heart Failure is Safe and Provides Clinical Benefit
9. Northwest Biotherapeutics to Present at American Society of Cell and Gene Therapy
10. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
11. Nile Therapeutics to Transition to OTCQB Marketplace
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Fort Washington, PA (PRWEB) , ... ... ... The Omnia-Prova Education Collaborative (TOPEC), the leading medical education provider of ... Accreditation with Commendation by the Accreditation Council for Continuing Medical Education (ACCME). ...
(Date:2/22/2017)... ... February 22, 2017 , ... LabRoots , the leading provider of ... world, is pleased to announce the launch of a new scholarship for young scientists ... , This merit-based scholarship is open to all high school seniors, 17 years or ...
(Date:2/22/2017)... 22, 2017 Aethlon Medical, Inc. (Nasdaq: ... study that validated the ability of the Aethlon Hemopurifier® ... increased mortality in immune-suppressed sepsis patients and also contribute ... The objective of the study was to validate the ... virus (EBV) and Herpes Simplex virus 1 (HSV1) by ...
(Date:2/22/2017)... PHOENIX and SAN DIEGO ... Technology Holdings (the "Company") (OTCQB:CELZ) announced today expansion ... universal donor stem cell product through establishment of ... initiated research activities at the San Diego BioLabs ... Companies, Boehringer Ingelheim, Novartis, and Sanofi. ...
Breaking Biology Technology:
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a ... announced that it has received Laboratory Accreditation from ... Accreditation is presented to laboratories that meet stringent ... demonstrate scientifically rigorous processes. "Genos is ... in laboratory practices. We,re honored to be receiving ...
(Date:2/13/2017)... FRANCISCO , Feb. 13, 2017  RSA ... centralized platform that is designed to enhance fraud ... latest release in the RSA Fraud & Risk ... enable organizations to leverage additional insights from internal ... tools to better protect their customers from targeted ...
(Date:2/10/2017)... , Feb 10, 2017 ... new report "Personalized Medicine - Scientific and Commercial Aspects" ... ... personalized medicine. Diagnosis is integrated with therapy for selection of ... on early detection and prevention of disease in modern medicine. ...
Breaking Biology News(10 mins):